Clinical trials: Solid Tumors, completed
Cancer
A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors
This research study is studying a combination of a targeted therapy and an immune therapy as a possible treatment. The drugs involved in this study are: Prexasertib (LY2606368) LY3300054
- Trial name
- NCT03495323
- Testing
- LY3300054, Prexasertib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Solid Tumors, Non-Small Cell Lung Cancer (NSCLC)
Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors
The purpose of this study is to find out if panobinostat taken with cisplatin and pemetrexed can be used safely without increasing side effects and that the combination will have a better effect than platinum-based doublet…
- Trial name
- NCT01336842
- Testing
- Panobinostat, Cisplatin, Pemetrexed
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- University of California, Davis
Breast Neoplasms, Lung Neoplasms
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
Given the role of mTOR signaling and probable synergistic activity of combining sirolimus and metformin in patients with advanced solid tumors, the investigators hypothesize that: 1.
- Conditions
- Breast Neoplasms, Lung Neoplasms, Cancer of Liver, Lymphoma
- Trial name
- NCT02145559
- Testing
- Metformin XR, Delayed Metformin, Sirolimus
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Chicago
Positron-Emission Tomography, Metastatic Solid Tumors
⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors
The purpose of this study is to evaluate the safety of repeat doses ⁸⁹Zr-Df-IAB22M2C and to establish the relationship between ⁸⁹Zr-Df-IAB22M2C PET/CT lesion uptake with CD8+ cells by immunohistochemical staining in patients with…
- Trial name
- iCorrelate (NCT03802123)
- Testing
- ⁸⁹Zr-Df-IAB22M2C
- Where
- 15 sites in United States
- Volunteers
- 52 people
- Sponsor
- ImaginAb, Inc.
Dyspnea, Pulmonary Complications
Buspirone in Reducing Shortness of Breath in Patients With Cancer
RATIONALE: Buspirone may be effective in reducing dyspnea (shortness of breath) in patients with cancer who are undergoing chemotherapy.
- Conditions
- Dyspnea, Pulmonary Complications, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00053846
- Testing
- buspirone hydrochloride
- Where
- 15 sites in United States
- Volunteers
- 432 people
- Sponsor
- University of Rochester
Neoplasms
A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.
The purpose of this study is to assess the safety of JNJ-26854165 (a new drug in development for cancer) in patients with advanced or refractory solid tumors on the maximum dose tolerated by these patients.
- Trial name
- NCT00676910
- Testing
- JNJ-26854165
- Volunteers
- 71 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Central Nervous System Metastases, Childhood Central Nervous System Choriocarcinoma
Sunitinib in Treating Young Patients With Refractory Solid Tumors
This phase I trial is studying the side effects and best dose of sunitinib in treating young patients with refractory solid tumors.
- Conditions
- Central Nervous System Metastases, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor
- Trial name
- NCT00387920
- Testing
- sunitinib malate, pharmacological study, dynamic contrast-enhanced magnetic resonance imaging
- Where
- 17 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors Amenable to Anthracycline Therapy, Sarcoma, Breast Cancer, Lung Carcinomas, and Gynecological Cancer Amenable to Anthracycline Therapy
L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours
Prospective, open-label, non randomized, dose escalation study that will be conducted in sequential cohorts of patients.
- Trial name
- NCT02076620
- Testing
- L19TNFα, Doxorubicin
- Where
- 2 sites in Germany, Italy
- Volunteers
- 29 people
- Sponsor
- Philogen S.p.A.
Advanced Solid Tumors
A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with select…
- Trial name
- NCT02261220
- Testing
- MEDI4736, tremelimumab
- Where
- 75 sites in United States, Canada and 7 more
- Volunteers
- 380 people
- Sponsor
- MedImmune LLC
Advanced Solid Tumors
A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors
The purpose of this study is to obtain QTc data, to assess the effects of tivozanib on ECG morphology, and to determine the pharmacokinetic pharmacodynamic (PK-PD) relationship between any observed changes in cardiac…
- Trial name
- NCT01210846
- Testing
- tivozanib
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Advanced Solid Tumors, Advanced or Metastatic Biliary Cancer
A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer
This is a Phase 1 study during which patients with advanced solid tumors will receive investigational study drug ARRY-438162 (MEK162). This study has 3 parts.
- Conditions
- Advanced Solid Tumors, Advanced or Metastatic Biliary Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT00959127
- Testing
- ARRY-438162 (MEK162), MEK inhibitor; oral
- Where
- 10 sites in United States
- Volunteers
- 93 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Unspecified Adult Solid Tumor, Protocol Specific
Endostatin in Treating Patients With Advanced Refractory Solid Tumors
RATIONALE: Endostatin may stop the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of endostatin in treating patients who have advanced refractory solid tumors.
- Trial name
- NCT00004872
- Testing
- recombinant human endostatin
- Where
- United States
- Sponsor
- University of Wisconsin, Madison
Advanced Solid Tumors
A Study of ABT-806 in Subjects With Advanced Solid Tumor Types
This is an open-label study designed to determine the recommended Phase 2 dose (RPTD) and evaluate the safety and pharmacokinetics of ABT-806 in subjects with advanced solid tumors.
- Trial name
- NCT01255657
- Testing
- ABT-806
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Unspecified Adult Solid Tumor, Protocol Specific
Vaccine Therapy in Treating Patients With Advanced Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have advanced cancer.
- Trial name
- NCT00004881
- Testing
- MVA-MUC1-IL2 vaccine
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Solid Tumors
Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors
The goal of this clinical research study is to learn if nivolumab combined with ISA101 can help to control cancer that has spread. The safety of the study drugs will also be studied. This is an investigational study.
- Trial name
- NCT02426892
- Testing
- ISA 101, Nivolumab
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Refractory Solid Tumors
A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors
Chemotherapy resistance, either innate or acquired requires for its development, expression changes on a large number of genes therefore, it has been hypothesized that epigenetic-mediated changes could be the responsible driving…
- Trial name
- NCT00404508
- Testing
- Hydralazine and magnesium valproate
- Where
- Mexico
- Volunteers
- 15 people
- Sponsor
- National Institute of Cancerología
Brain and Central Nervous System Tumors, Lymphoma
Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: : Phase I trial to study the effectiveness of gallium nitrate in young patients who have malignant…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Sarcoma
- Trial name
- NCT00002543
- Testing
- gallium nitrate
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Medical College of Wisconsin
Solid Tumor
S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
The purpose of the study is to investigate the safety, tolerability, and preliminary anti-neoplastic activity of S095029 alone and in combination with Sym021 in patients with advanced solid tumor malignancies followed by an…
- Trial name
- NCT05162755
- Testing
- S095029, S95029 and Sym021
- Where
- 5 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Institut de Recherches Internationales Servier
Solid Tumor
A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors
This was a multicenter, open, multi-cohort extended PHASE I/IIa study, consisting of 2 phases:Phase I (Phase I dose escalation) and Phase II (Phase IIa multi-cohort extension).
- Trial name
- NCT04175847
- Testing
- RC88
- Where
- 4 sites in China
- Volunteers
- 198 people
- Sponsor
- RemeGen Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.